Cytokines in Metabolic Functions by Benrick, Anna
  
CYTOKINES IN METABOLIC FUNCTIONS 
 
Anna Benrick 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section of Endocrinology 
Institute of Neuroscience and Physiology 
The Sahlgrenska Academy at University of Gothenburg 
Sweden 2008 
 
  
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Anna Benrick 
Göteborg, Sweden, 2008 
The cover was designed by Maria Berndtsson 
Printed by Intellecta DocuSys AB, Göteborg 
ISBN 978-91-628-7414-8 
 
ABSTRACT 
 
3 
ABSTRACT 
During infections, circulating cytokines are largely produced by immune 
cells. In healthy obese individuals, large parts of these circulating 
cytokines are produced in adipose tissue, for instance by macrophages 
that have accumulated there. The aim of this thesis was to investigate the 
role of cytokines, in particular interleukin-6 (IL-6), IL-1β and leukemia 
inhibitory factor (LIF), in the regulation of metabolism and body fat mass. 
Furthermore, we also wanted to examine the role of the IL-6 signal 
transducer (IL6ST)/gp130 receptor signalling. 
 
We have previously shown that IL-6 depleted (IL-6 -/-) mice develop late-
onset obesity and we have now found a similar effect on IL-1 depletion. 
We have used IL-1 receptor type I depleted (IL-1RI -/-) mice to study the 
role of endogenous IL-1 on obesity, as measured by DEXA. The obesity in 
IL-1RI -/- was accompanied by decreased insulin and leptin sensitivity. 
Spontaneous locomotor activity and fat utilization, as measured in 
metabolic cages, were decreased in pre-obese IL-1RI -/- animals. At the 
hypothalamic level, deficiency of endogenous IL-1 activity in knockout 
mice was associated with enhanced expression of the obesity promoting 
peptides NPY and MCH, and decreased expression of the obesity 
suppressing peptide orexin. In IL-6 -/- mice, the expression of 
corticotrophin releasing hormone, a known stimulator of energy 
expenditure and the sympathetic nerve system, was decreased, as shown 
by RT-PCR. Moreover, endogenous IL-6 and IL-1β seemed to affect each 
others’ expression in the hypothalamus. Therefore, IL-6 and IL-1 may 
interact in the CNS, presumably in the hypothalamus, to suppress fat 
mass, possibly by increasing energy expenditure and maybe especially fat 
burning. 
 
LIF is a member of the IL-6 receptor family, which shares the                 
IL6ST/gp130, and has been reported to decrease obesity. We found that 
systemic LIF treatment could reduce white and brown fat depots in 
ovariectomized mice, suggesting that LIF can reduce obesity 
independently of estrogen signalling. 
 
Obesity and inflammation are key components in the development of 
atherosclerosis and myocardial infarction. We identified an association 
between an IL6ST/gp130 polymorphism in amino acid 148 (Gly/Arg) and 
risk of myocardial infarction in a hypertensive population. In vitro studies 
showed decreased proliferation and lower STAT-3 phosphorylation in cells 
transfected with gp130 148Arg compared to gp130 148Gly. Structural 
modelling suggested changes in the stability and functional properties of 
the gp130 148Arg molecule. 
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The present results suggest that the cytokines IL-6, IL-1 and LIF are 
involved in the regulation of body fat mass and energy expenditure. The 
effects of IL-6 and IL-1 may be exerted at the CNS level and involve 
altered expression of hypothalamic peptides regulating fat mass and 
energy expenditure. This can constitute a possible mechanism contributing 
to the mature-onset obesity in IL-6 -/- and IL-1RI -/- mice. LIF may 
suppress obesity via estrogen independent effects in the periphery. In 
human subjects, the 148th amino acid arginine of the gp130 receptor is 
associated with decreased risk of myocardial infarction, possibly due to an 
impaired responsiveness to cytokines in the IL-6 receptor family. 
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ABBREVIATIONS 
AgRP  agouti-related protein 
ARC  arcuate nucleus 
BAT  brown adipose tissue 
CNS  central nervous system 
CNTF  ciliary neurotrophic factor 
CRH  corticotrophin releasing hormone 
CVD  cardiovascular disease 
DMN  dorsomedial nucleus 
HPA  hypothalamic-pituitary-adrenal 
ICV  intracerebroventricular 
IL-1  interleukin-1 
IL-1Ra interleukin-1 receptor antagonist 
IL-6   interleukin-6 
IL-6Rα interleukin-6 receptor α 
IL6ST interleukin-6 signal transducer 
i.p.  intraperitoneally 
i.v.  intravenously 
LHA  lateral hypothalamic area 
LIF  leukemia inhibitory factor 
LIFR  leukemia inhibitory factor receptor 
LPS  lipopolysacharide 
MCH  melanocyte concentrating hormone 
NPY  neuropeptide Y 
NTS  nucleus of the solitary tract  
OVX  ovariectomized 
POMC pro-opiomelanocortin 
PVN  paraventricular nucleus 
RER  respiratory exchange ratio 
SNP  single nucleotide polymorphism 
SNS   sympathetic nerve system 
TNF-α tumour necrosis factor-α 
UCP  uncoupling protein 
VMN  ventromedial nucleus 
-/-  depletion 
 
Abbreviations occurring only once or twice in the text are generally spelt 
out where they occur. 
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INTRODUCTION 
Metabolic Regulation  
The history of the scientific study of metabolism stems from 1614 when 
Italian Santorio described how he weighed himself before and after eating, 
sleeping, working, fasting, drinking, and excreting. He found that most of 
the food he took in was lost through what he called insensible perspiration 
[1]. 
 
Metabolism is the chemical reactions that occur in the body to convert the 
food we eat into energy. Since energy can not be created or destroyed, 
according to the first law of thermodynamics, it has to be used or stored 
within the body. The metabolic processes in the body do not happen at 
random, but are tightly regulated to enable use of the energy in ingested 
food in the most efficient way. This is especially important as energy 
intake usually is not matched with energy demanding activities. Therefore, 
the ability to store energy that can be released when needed is crucial for 
survival. The metabolic regulation depends mainly on endocrine and 
neuronal systems derived from the central nervous system (CNS) and 
periphery, to maintain homeostasis. These systems sense the energy 
balance and regulate the storage and release of energy [2]. In the end the 
metabolic regulation occurs at a molecular level by modulations of enzyme 
activity. A striking feature of metabolism is the similarity of the basic 
metabolic pathways between vastly different species, a result of early 
appearance in evolutionary history, and the high efficiency of these 
pathways. 
 
Obesity 
Definition and Consequences 
Obesity was once considered a symbol of wealth and social status, but in 
modern Western culture were food supply mostly is secured, the obese 
body shape is widely regarded as unattractive and obesity is often seen as 
a sign of lower socio-economic status [3]. However, obesity should not be 
considered only as a cosmetic problem. In clinical practice, obesity is 
viewed as a serious public health problem, with reduction in life 
expectancy. In fact, obesity is a major risk factor for cardiovascular 
disease (CVD), e.g. atherosclerosis, hypertension, stroke, and myocardial 
infarction, and type-2 diabetes, sleep apnea, depression and certain 
cancers [3, 4].  
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The definition of obesity varies, but clinically it may be regarded as a 
chronic condition in which body fat is increased to a point where it is a 
health hazard. 
 
”The Thrifty Genotype”-Hypothesis 
It is widely accepted that obesity is the result of interaction between genes 
and the surrounding environment. In 1962 James Neel suggested that the 
human population carries a genetic predisposition to store body fat, 
because, during the first 99% of Homo sapiens life on earth, when we 
lived in hunter and gatherer cultures, there was often either feast or 
famine. During periods of famine selection would favour individuals that 
had been more successful in body fat deposition, i.e. individuals with 
thrifty genes [5]. In the modern world, where food is available in 
abundance, we are programmed to deposit fat in preparation for a famine 
that never comes. Therefore, we see an increase in the frequency of 
obesity as more and more people have come to enjoy the blessings of 
civilization. Still, if thrifty genes had a selective advantage, why did not 
the 35-40% of the population that has stayed lean inherit these genes? 
 
Recently, the thrifty genotype hypothesis has been questioned, mainly 
because famines are rare and infrequent phenomena that are insufficient 
for thrifty genes to propagate [6]. Instead, it was suggested that the 
absence of human predation around two million years ago, led to changes 
in body fat mass due to random mutations rather than direct selection. 
Under predation pressure, the risk of starvation and poor immune 
response keeps body masses up while the risk of being killed by a predator 
keeps body masses down, resulting in small variations in body fat mass 
[6]. Consequently, the absence of predation removes the upper limit of 
body mass, allowing a drift upwards resulting in obesity, while there still is 
a strong disease-related selection against too low body masses. Moreover, 
since the upward drift is presumed to happen at random, this can explain 
why many individuals are still normal weigh.  
 
Whatever theory that is put forward to explain body weight and fat 
regulation, it follows the first law of thermodynamics; that changes in body 
fat can not occur unless there is a difference between energy intake and 
energy expenditure. 
 
CNS Regulation of Energy Balance 
CNS Control of Body Weight 
Many adult people maintain a relatively stable body weight throughout life 
and human and animal studies show that individuals that are forced to 
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over eat during shorter periods return to their initial body weight when 
allowed to eat only as much as they please [7]. This suggests that each 
individual has its own set-point and that a change in body weight is 
counteracted by regulatory processes of energy homeostasis. Moreover, 
despite great variations in daily calorie intake and physical activity, the 
total energy intake tends to match energy expenditure over time     
(Figure 1).  
 
Energy Expenditure Energy Intake
Availability of food
Regulation of appetite
“Uptake from gut”
Basal metabolic rate
Adaptive thermogenesis
Physical activity
 
Figure 1. Energy balance and its components 
The first law of thermodynamics states that energy can neither be created nor be 
destroyed. Thus, if the energy intake exceeds the energy expenditure, the 
remaining energy will be stored. Both energy intake and energy expenditure are 
regulated by biological control mechanisms, which aim to achieve long-term energy 
balance and a stable body weight. Adapted from Spiegelman et. al.[8]. 
 
Energy homeostasis and body weight is maintained relatively constant by 
nutrient signalling from the periphery to the CNS and back. This requires 
input from endocrine and neural signals, produced in proportion to body 
fat content, informing the CNS of the current energy status of the body.  
 
Adiposity signals like leptin and insulin interact with pathways in the 
hypothalamus, stimulating satiety and energy expenditure. Afferent 
signals from the liver and the gastrointestinal tract are transmitted 
through the vagus nerve and sympathetic nerve fibres to the nucleus of 
the solitary tract (NTS), where they are integrated with hypothalamic input 
[2, 9]. Moreover, leptin action in the arcuate nucleus (ARC) has been 
shown to regulate brainstem response to satiety signals in the NTS, via 
connections between the hypothalamus and brainstem [10] (Figure 2). 
 
Hypothalamic Regulation of Energy Intake and Expenditure 
Electrical stimulation and lesion studies in the 1940´s and 50´s showed 
that there is a satiety centre in the hypothalamus (now known to include 
ventromedial nucleus (VMN) and the ARC), and that these parts of the 
hypothalamus send inhibitory projections to the hunger centre in the 
lateral hypothalamic area (LHA) [11]. Two orexigenic peptides have been 
found in the LHA, melanocyte concentrating hormone (MCH) [12] and 
orexin [13], supporting previous findings that this is a hunger centre. Later 
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it also became clear that the hypothalamus is important for the regulation 
of energy expenditure [11]. 
PVN LHA
ARC
Insulin
Leptin
NTS
n. v
agus
SN
S a
ffe
re
nt
s
VMH
DMN
SNS
Feeding
Metabolic rate
 
Figure 2. Adiposity signals to the ARC interact with central autonomic 
circuits to regulate body weight 
Adiposity signals, such as leptin and insulin are transported with the blood to the 
brain where they interact with the arcuate nucleus (ARC), which in turn project to 
the paraventricular nucleus (PVN) and lateral hypothalamic area (LHA) within the 
hypothalamus. Afferent satiety signals from the gastrointestinal tract and the liver 
travel via the vagus nerve and sympathetic nerves to neurons in the nucleus of the 
solitary tract (NTS) in the brainstem. There is reciprocal interaction between the 
brainstem and the hypothalamus. The hypothalamus regulates anabolic and 
catabolic pathways to affect satiety signals and energy expenditure mediated by 
efferents in the sympathetic nervous system (SNS). Adapted from Schwarts et. al. 
[2]. 
 
Today the regulation of food intake and energy expenditure is thought to 
be organized in neuronal networks, projecting between different structures 
of the brain. The ventromedial part of hypothalamus, consisting of the 
VMN and ARC, serves as a central integrator of numerous peripheral 
afferent signals. Through neurotransmitter systems located within the 
paraventricular nucleus (PVN) and the LHA, these afferent signals are 
transduced into efferent signals, which control food intake and metabolic 
rate. The dorsomedial nucleus (DMN) has extensive connections with the 
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ventromedial part of hypothalamus and LHA and DMN integrate and 
process information from these nuclei. Areas in PVN and LHA are richly 
supplied by axons from the ARC, and neurons of the PVN and LHA, in turn, 
project to the ARC, creating a bidirectional communication between ARC 
and the second order neurons of PVN and LHA (Figure 3).  
 
Numerous neuronal pathways implicated in energy balance regulation 
converge in the PVN, the main site of secretion of corticotrophin releasing 
hormone (CRH) and thyrotrophin releasing hormone. For instance, 
nutritional signals to the hypothalamic-pituitary-adrenal (HPA) axis are 
integrated in the PVN [9]. A great deal has been learned about the 
hypothalamic control of appetite and energy balance following the 
discovery of leptin in 1994, based on the fact that these hypothalamic 
systems are downstream targets of leptin action [14]. 
 
Leptin 
Leptin is a circulating satiety peptide produced by white adipose tissue 
that mediate information about energy stores to the ARC and VMN. 
Centrally, it interacts with key anorexigenic and orexigenic systems to 
reduce food intake and activate the sympathetic nervous system (SNS) 
[15] (Figure 3). The complete absence of leptin leads to a syndrome of 
intense hyperphagia and morbid obesity in humans and rodents [16, 17] 
which can be reversed by recombinant leptin treatment [18, 19].  
 
An obvious question is why leptin has proved disappointing for the 
treatment of regular obesity despite the fact that the central regulation of 
fat mass is so dependent on leptin? Obese subjects generally already have 
high levels of serum leptin and can be considered to be leptin resistant. 
One possible reason for this is an impaired transport of leptin into the 
CNS, maybe simply due to overloaded transport capacity in the presence 
of high leptin levels [20-22]. However, resistance could also occur at the 
neuron level, possibly mediated by excessive suppressor of cytokine 
signaling-3 (SOCS-3) activity in leptin-responsive cells [23], a state seen 
in mice with obesity induced by high fat diet, which show impaired 
response to ICV injected leptin [24]. It is possible that the principal 
purpose of leptin was not the prevention of obesity, but to be a signal 
giving the brain information about prolonged fasting and loss of body fat 
[8, 25]. Thus, leptin was maybe never designed to act at the plasma level 
that is now seen in our over-nourished western society. However, it seems 
like each individual has a personal leptin threshold for sensing nutrient 
status and that this threshold can be shifted upwards in obesity [26]. If 
the level of adiposity and leptin serum levels drop below this value, the 
ventromedial hypothalamus senses starvation. Consequently, in the leptin 
deficient state appetite and energy storage are promoted and energy 
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expenditure is reduced [9, 27]. Obese persons may manifest the 
starvation response at a higher level of leptin, which counteract weight 
loss and reduce quality of life.  
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Figure 3. Schematic presentation of the hypothalamus 
Cross section of the hypothalamus showing important areas for food consumption 
and energy expenditure regulation. Orexigenic and anorexigenic signals are 
depicted to the left and the right of the third ventricle, respectively. Leptin up-
regulates anorexigenic signals and down-regulates orexigenic signals. Arcuate 
nucleus (ARC), ventromedial nucleus (VMN), lateral hypothalamic area (LHA), 
paraventricular nucleus (PVN), agouti-related protein (AgRP), alpha-melanocyte-
stimulating hormone (α-MSH), corticotrophin-releasing hormone (CRH), melanin-
concentrating hormone (MCH), neuropeptide Y (NPY), pro-opiomelanocortin 
(POMC). Adapted from Crowley et. al. [28] 
 
The Arcuate Nucleus 
Although the brain is protected against circulating toxins by the blood-
brain-barrier, there is a lack of blood-brain-barrier in the median eminence 
area, located in the mediobasal hypothalamus. The median eminence 
represents a particularly important region, as it is a small area where the 
interplay between peripheral organs and the brain takes place. The ARC 
directly overlies the median eminence and some arcuate neurons are, by 
having specific receptors for blood-borne hormones and nutrients such as 
leptin and insulin, able to sense the metabolic state of the organism [2].  
 
The first order neurons in the ARC receive first hand information regarding 
nutritional status. Neuropeptide Y (NPY) and agouti-related protein (AgRP) 
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are co-expressed in the medial ARC and regulate MCH and orexin neurons 
in the LHA as well as thyrotrophin releasing hormone and CRH in the PVN 
[2, 29]. NPY and AgRP stimulate feeding and decrease energy expenditure. 
In contrast, pro-opiomelanocortin (POMC) and cocaine-amphetamine 
regulated transcript (CART), also produced in the ARC, decrease feeding 
and increase energy expenditure. Leptin directly inhibits expression of NPY 
and directly stimulates POMC and CART, while it indirectly inhibits MCH 
and orexin [2, 29] (Figure 3). As lesions of the ventromedial hypothalamus 
result in obesity, it seems that obesity suppressing POMC and CART 
containing neurons are dominant, and the NPY- and AgRP-containing 
neurons mainly modulate the action of the former neurons. The action of 
peripheral signals on these neurons triggers a cascade of neuronal events 
in higher CNS centres, resulting in autonomic effectors that regulate 
energy intake and expenditure. 
 
Cytokines in Inflammation, Metabolic Regulation and 
CVD 
 
Cytokines 
Cytokines are a group of smaller water-soluble proteins and peptides that 
are used in intracellular communication through receptor-ligand interaction 
and can have effects on both nearby cells or throughout the organism. 
Cytokines have been variously named as lymphokines, interleukins and 
chemokines, based on their presumed function, cell of secretion or target 
of action. Since cytokines are characterized by considerable redundancy 
and pleiotropism, and have physiological actions far beyond those 
originally discovered, such distinctions may be out-of-date.  
 
Cytokines are produced by a wide variety of cell types (e.g. haemopoietic 
and glia cells, hepatocytes, adipocytes, myocytes and maybe also 
neurons). Circulating cytokines are predominantly produced by cells of the 
innate immune system (i.e. monocytes and macrophages) [30], and are 
involved in a variety of immunological, inflammatory and infectious 
diseases.  
 
Some cytokines can elicit reverse effects depending on the in vivo 
environmental circumstances [31]. Therefore it is important to take into 
account where, i.e. central or peripheral effects, and under which 
conditions, e.g. exercise, infection, obesity or normal state, cytokine 
effects are being investigated. However, not all their functions are limited 
to the immune system, as they are also involved in several developmental 
processes during embryogenesis, reproduction and cardiovascular 
function, and more recently they have been shown to be important in the 
regulation of metabolic functions [32-35] (Figure 4). 
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Figure 4. The pleiotropy of cytokines 
Cytokines can modulate various biological responses e.g. proliferation, survival and 
apoptosis in several organs. Acute phase response (APR) 
 
Metabolic Regulation of Cytokines in Sickness  
It is well known that the immune system is energy consuming and 
maintenance of immune functions has been estimated to account for as 
much as 15% of the daily energy expenditure in healthy individuals [36] 
and even more during infection. When the immune system is fighting 
pathogens, a special group of cytokines (chemokines) signal immune cells 
such as T-cells and macrophages to travel to the site of infection. Once the 
cells are there, cytokines activate them and stimulate production of even 
more cytokines [37]. Many metabolic processes respond directly or 
indirectly to proinflammatory cytokines to ensure an adequate supply of 
nutrients for proliferation of lymphocytes and macrophages, antibody 
production and hepatic synthesis of acute phase proteins. The prevailing 
hypothesis is that during periods of immune challenge, cytokines direct 
nutrients away from tissue growth and other non-immune functions in 
support of the immune defence [38]. Consequently, infection causes major 
alteration in the metabolism. In this state glucose uptake by peripheral 
tissue is reduced and cytokines block the suppression of hepatic 
gluconeogenesis by insulin. Since energy intake is typically reduced in 
sickness, fatty acid oxidation is increased to provide energy and protein 
degradation is increased to supply amino acids for production of acute 
phase proteins [38].  
 
To date, the knowledge of fuel utilization by immune cells is limited and 
available data is mostly based on in vitro studies. However, the collected 
picture suggests that immune cells use glucose as their main fuel and this 
is facilitated, in part, by increased expression of glucose transporters [39, 
40]. In addition, immune cells express the insulin receptor and respond to 
insulin [40]. Furthermore, glutamine seems to be essential for optimal 
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immune cell function and is highly used both as a primary fuel and as a 
carbon and nitrogen donor for nucleotide precursor synthesis [41]. 
Although fatty acids are used as fuel, but at a lower rate, their oxidation 
does not appear to be crucial for immune cell function [39]. 
 
Proinflammatory cytokines do not only affect the metabolism of specific 
nutrients, but also act in the brain to induce fever and psychological and 
behavioural changes, called sickness behaviour, that influence whole-body 
energy balance. By preventing metabolically expensive non-immune 
activities (e.g. foraging, social interaction) and favouring those that 
decrease heat loss and increase heat production (e.g. rest and shivering), 
infection is associated with fever and anorexia [37]. This increase in 
metabolic rate together with a reduction in appetite may cause a negative 
energy balance, loss of lean body mass and consequently cachexia [42].  
 
Systemic cytokines can cause sickness behaviour by inducing expression 
of cytokines in the brain via one or two of the following routes; blood-
borne cytokines can enter the brain directly via transport across the blood-
brain barrier [21]. Alternatively endogenous cytokines are produced and 
released in the brain in response to peripheral cytokines, possibly via the 
vagus nerve [42]. The exact mechanisms behind the induction of these 
responses are not known, but cytokines are no doubt involved in the 
regulation of fever and sickness behaviour [37, 42]. 
 
Metabolic Regulation of Cytokines in Health 
Adipose tissue was previously regarded as a rather passive tissue, which 
primary role was to store and release fat in response to the body’s energy 
needs. However, mature adipocytes account for only half of the total cell 
numbers in adipose tissue, where they share the space with fibroblasts, 
endothelial cells, pre-adipocytes and macrophages. Nowadays, adipose 
tissue is considered a highly active endocrine organ secreting a range of 
biologically active substances. These proteins, synthesized by and released 
from the adipocytes and/or adipose tissue, are termed adipokines and are 
often cytokines, e.g. tumour necrosis factor-α (TNF-α), interleukin-6     
(IL-6), leukemia inhibitory factor (LIF), interleukin-1β (IL-1β) and 
interleukin-1 receptor antagonist (IL-1Ra) [43-46].  
 
Adipokines are involved in a wide range of physiological and metabolic 
processes e.g. lipid metabolism, glucose homeostasis, inflammation and 
energy balance [43]. The expression and release of inflammatory 
cytokines are increased in adipose tissue with obesity and increased 
circulating levels of these proteins have been suggested to be important 
for the development of obesity related disease, in particular insulin 
resistance and CVD [47, 48]. The most famous adipokine is leptin and the 
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primary finding is that leptin decreases appetite and increases energy 
expenditure via effects exerted on the hypothalamus. However, similarly 
to other cytokines (Figure 4), leptin is involved in many biological 
processes and is also involved in metabolism and immune response. Leptin 
has direct effects on adipose tissue by inhibiting lipogenesis and 
stimulating lipolysis [49]. Leptin synthesis is increased during infection 
when high circulating levels of leptin no longer correlate with body fat 
mass and possibly also contribute to anorexia and weight loss [25]. 
 
In contrast to leptin, IL-6 and members of the IL-1 family were initially 
identified as regulators of immune response. In healthy individuals, a large 
part of circulating IL-6 and IL-1Ra is produced in adipose tissue e.g. by 
adipocytes and macrophages. The role of cytokines, e.g. IL-6, IL-1 and 
LIF, in healthy animals and humans is not well known but has been 
suggested to be of little importance, partly because circulating levels often 
are low in the absence of infection or severe stress. However, if a 
metabolically active cytokine like leptin also is involved in regulation of the 
immune system it is not unlikely that other cytokines play a role in 
metabolic regulation. Furthermore, an increasing number of polymorphism 
studies show that genetic variations in the IL-6 and IL-1 system genes are 
associated with both changed activity and expression of these genes, as 
well as alterations in body fat mass [50-55]. These effects might be 
exerted at the level of the CNS, as IL-6 and IL-1 knockout mice develop 
mature-onset obesity [32, 34]. Moreover, centrally administered IL-6 and 
LIF can decrease body fat without causing acute-phase reaction [56, 57] 
and a single ICV injection of IL-6 or IL-1 increases energy expenditure 
[34, 58]. 
 
Cytokines in Inflammation and CVD 
Obesity is associated with an increased risk of CVD [3] and is linked to a 
state of chronic inflammation [59], as overweight and obese subjects have 
elevated serum levels of C-reactive protein, IL-6 and TNF-α, all known 
markers of inflammation. Inflammation is a key component in the 
development of atherosclerosis and systemic inflammation is often 
associated with increased risk of cardiovascular events, i.e. myocardial 
infarction, stroke and peripheral artery disease. It has been hypothesized 
that proinflammatory cytokines from adipose tissue contribute to chronic 
inflammation and thereby also to CVD.  
 
IL-6 is a powerful inducer of the acute phase response [60], and the acute 
phase reactant C-reactive protein is an important predictor and strong risk 
factor for CVD [61]. Other proinflammatory cytokines, like IL-1β and   
TNF-α, are also able to regulate the acute phase response. However, 
animal studies indicate that the role of IL-6 is the primary one since only 
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IL-6 -/- mice show an impaired acute phase response, while IL-1β and 
TNF-α knockout animals show normal responses [60]. Furthermore, in 
vitro studies suggest that IL-6 is expressed to a greater extent in visceral 
than subcutaneous fat [62]. This fits well with the association between 
visceral fat mass and risk of CVD. Moreover, the IL-6 signal transducer 
(IL6ST)/gp130 is a key component in the inflammatory signal pathway. 
Recently we (Paper IV) and others [63] have provided evidence that 
variations in gp130 activity can influence the risk of atherosclerosis, 
coronary artery disease and myocardial infarction. 
 
Receptors and Signal Transduction 
The effect of a particular cytokine on a given cell depends on the levels of 
the cytokine, the abundance of the complementary receptor on the cell 
surface, and downstream signals activated by receptor binding. Each 
cytokine binds to a specific cell-surface receptor. Subsequent cascades of 
intracellular signalling then alter cell functions. Interestingly, cytokines are 
characterized by considerable "redundancy", in that many cytokines 
appear to share receptor subunits and exert similar functions [64-66]. 
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Figure 5. IL-1 signalling 
IL-1β and the members of IL-1 family of ligands: IL-1α/β and IL-1 receptor 
antagonist (IL-1Ra) act through a heterodimer consisting of the IL-1 type I receptor 
(IL-1RI) and IL-1 accessory protein (IL-1AcP). Binding of agonist induces the 
recruitment of MyD 88 and initiates the activation of IRAK/TRAF pathway leading to 
nuclear factor-kappaB (NF-κB) activation. 
 
The IL-1 family consists of IL-1β, IL-1α and the endogenous receptor 
antagonist IL-1Ra which all bind to the same receptors; the type I and 
type II IL-1 receptors. The heterodimeric IL-1RI complex is composed of 
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the IL-1RI and the IL-1 accessory protein (IL-1AcP) and is responsible for 
signal transduction, while the IL-1RII acts as a “decoy” receptor unable to 
activate the signalling cascade [67]. Binding of IL-1 drives dimerization of 
the IL-1RI with its accessory protein, followed by recruitment and 
phosphorylation of the IL-1 receptor-associated kinase (IRAK) via the 
docking molecule MyD88, leading to nuclear factor-kappaB (NF-κB) 
activation [68] (Figure 5). 
 
IL1Ra acts as a negative regulator of IL-1β and IL-1α actions. IL-1Ra -/- 
mice (excess IL-1 signalling) are lean and resistant to diet induced obesity, 
and have increased energy expenditure and low serum insulin levels 
without changes in food intake [69, 70]. Conversely, IL-1Ra, which is 
produced by the white adipose tissues, is up-regulated in the serum of 
obese humans and experimental animals [44, 71].  
 
The IL-6 cytokine family consisting of IL-6, IL-11, oncostatin M, LIF, ciliary 
neutrophic factor (CNTF) and cardiotrophin-1, shares the gp130 signal 
transducer and signal through gp130 and a ligand specific receptor [30]. 
Although there is some crosstalk among the gp130 cytokines, the 
signalling pathway is not common to all family members. The gp130 is 
ubiquitously expressed across all cell types but it can not transduce signals 
without the ligand specific receptor which is expressed more selectively. 
The LIF receptor (LIFR) is ligand specific but is also present in the receptor 
complexes for oncostatin M, CNTF and cardiotrophin-1. In contrast to 
gp130 and LIFR, the cytoplasmic domain of IL-6 receptor α (IL-6Rα) is not 
necessary for signal transduction and the IL-6Rα exists in a soluble form 
(sIL-6Rα) that acts in an agonistic manner called transsignaling, allowing 
stimulation of cells only expressing gp130 [72].  
 
However, the scenario is more complex since gp130 and the LIFR also 
exist in a soluble form, which act in an antagonistic way by binding to 
circulating IL-6 and LIF respectively and thereby limit transsignaling and 
unspecific endocrine effect of IL-6-family-cytokines [73, 74]. The gp130 
receptor shares a large degree of homology with the long form of the 
leptin receptor, as both activate the JAK-STAT (janus kinase – signal 
transducer and activator of transcription) signalling pathway [64], which 
subsequently activates pathways important in energy balance, i.e. mTOR 
(mammalian target of rapamycin) [75] and PI3K (phosphatidylinositide 3-
kinase) [76, 77]. Furthermore, phosphorylated STAT-3 induces 
suppressors of cytokine signalling (SOCS) proteins, which lead to inhibition 
of cytokines by dephosphorylation of components in the signalling 
transduction cascade [78, 79]. Stimulation of gp130 cytokines can also 
lead to activation of the MAPK (mitogen-activated protein kinase) 
signalling pathway [80, 81] (Figure 6).  
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Hyper-IL-6 is a highly active designer cytokine consisting of IL-6 and sIL-
6Rα [82]. The fusion protein Hyper-IL-6 is 100-1000 times more active 
than the separate proteins IL-6 and sIL-6R. Hyper-IL-6, which has been 
used in Paper IV, can be used to stimulate several types of target cells, 
which are not stimulated by IL-6 alone, as they do not express the 
membrane bound IL-6Rα.  
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Figure 6. IL-6 family signalling 
The IL-6 cytokine family shares the gp130 signal transducer and signal through 
gp130 and a ligand specific receptor. The IL-6/IL-6Rα fusion-protein Hyper-IL-6 can 
activate all cells with gp130, in the absence of the ligand specific receptor. Binding 
of agonist induces phosphorylation of JAK and initiates the activation of JAK/STAT or 
JAK/MAPK pathway. Subsequent SOCS-3 stimulation leads to inhibition of the 
cytokine signalling transduction cascade. 
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CNS Expression of Cytokines and Receptors 
Cytokines and cytokine receptors have been found in the CNS and are 
expressed both under pathophysiological and normal conditions. In the 
CNS it has been reported that IL-6, IL-1 and LIF are synthesized mainly by 
microglia cells and also from astrocytes, and that their expressions 
increase dramatically during acute phase response and brain injury [83]. 
However, as indicated below there are also data indicating that these 
cytokines can be produced centrally by neurons. 
 
IL-1, and other cytokines, act on the brain via two pathways; one neuronal 
route represented by the primary afferents neurons that innervate the 
body site where the infection takes place and one humoral pathway. The 
first involves the production of IL-1 by microglia cells in the choroid 
plexus, and the latter the effects by circulating IL-1 on the brain at the 
circumventricular organs followed by diffusion of IL-1 to brain cells 
expressing IL-1 receptors. IL-1RI is diffusely spread across the brain, with 
the highest level of neuronal expression in the hypothalamus and 
hippocampus and in non-neuronal cells in the choroid plexus [68]. The 
ARC contains cells that express low levels of IL-1RI [84], and 
hypothalamic expression of IL-1RI is activated by central injections of IL-
1β or lipopolysaccaride (LPS) [85, 86]. 
 
IL-1β and IL-1Ra in the hypothalamus are induced by IL-1β or LPS 
administrated to the brain [85, 86]. IL-1β is expressed in the dorsal 
hypothalamus and pituitary. IL-1Ra on the other hand, is markedly 
induced in the hippocampus and cortex and to a lesser extent in the 
hypothalamus after peripheral LPS administration. The LPS induced IL-1Ra 
expression may stand for an attempt to balance IL-1RI activity after an 
injury or infection. The IL-1RAcP is expressed at a high level in the 
hypothalamus and all other regions tested, and is much more abundant in 
the brain than at the periphery [68].  
 
IL-6 and IL-6Rα mRNA have been reported to be expressed in the 
hippocampus, VMN and DMN of the hypothalamus [87] and IL-6 is rapidly 
stimulated by LPS injections that generate IL-6 transcription in the choroid 
plexus and median eminence [88]. IL-6Rα is also expressed in the 
parvocellular neurons in PVN and in median eminence [88]. Using 
immunohistochemistry, our studies show that IL-6 and IL-6Rα is 
expressed in the ARC, PVN, anterior hypothalamic area and supraoptic 
nucleus in untreated mice. Conversely gp130 is ubiquitously distributed 
throughout the brain and sgp130 is expressed at high levels in the 
cerebrospinal fluid; 100 times more than sIL-6Rα and 100.000 times more 
than IL-6 [89]. 
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Less is known about the distribution of LIF and LIFR in the brain; however 
some measurements indicate that LIF and its receptor are expressed in the 
hypothalamus and pituitary [90, 91].  
 
In summary, IL-6, IL-1 and LIF are all expressed in the hypothalamus and 
we hypothesize that this is the central site of action for the metabolic 
effects induced by these cytokines.  
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AIMS 
General Aims 
The basis of this thesis was the previously reported mature-onset obesity 
in IL-6 -/- mice. In the light of this we wanted to investigate whether other 
cytokines, such as IL-1β and LIF, are involved in the regulation of 
metabolism and body fat mass. Secondly we aimed to identify possible 
hypothalamic mechanisms by which IL-6 and IL-1 exert their effects on 
metabolism and obesity. Finally, we investigated whether genetic 
variations in cytokine signalling pathways are important for the 
cardiovascular consequences of metabolic diseases. 
 
Specific Aims 
The specific aims for each individual paper were: 
 
Paper I:  To investigate the effects of endogenous IL-1 on body fat 
mass and metabolism.  
 
Paper II:  To identify possible hypothalamic mechanisms by which IL-6 
and IL-1 exerts its effects on metabolism and obesity. 
 
Paper III:  To investigate the effect of LIF, a well known stimulator of 
the IL-6 signal transducer, on body fat mass. 
 
Paper IV:  To study the association between genetic variants of the IL-6 
signal transducer and the risk of myocardial infarction, a 
disease coupled to obesity and metabolic disturbances. 
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METHODOLOGICAL CONSIDERATIONS 
Genetically Modified Mice 
Rodents are a good model for studying basic physiological functions of 
mammals and have proved to be powerful models for understanding 
obesity in humans. Mice, the most commonly used vertebrate species, are 
widely considered to be an acceptable model of inherited human disease 
and share 99% of their genes with humans. The reasons for the popularity 
of the mouse are convenience of breeding and, especially, the introduction 
of genetic engineering technology. Genetically modified mice have been 
used successfully to discover genes and pathways that can regulate body 
weight and body fat. C57BL/6 is a common inbred mouse strain that is 
widely used as "genetic background" for genetically modified mice. It is 
particularly appreciated in the obesity and diabetes research area as it 
develops obesity and insulin resistance when fed a high fat diet [92]. 
 
Because of the multitude and complexity of the disturbances in energy 
homeostasis that are associated with obesity, it has been difficult to 
determine which abnormalities that are causative versus less important 
phenomena in this metabolic state. Moreover, obesity is a disorder that in 
most cases depends on several factors, such as environmental and genetic 
factors. Therefore, the degree of obesity of a knockout mouse is not easy 
to predict since the outcome depend on factors like diet, litter size, 
handling, room temperature, pathogens and maternal factors. One also 
has to keep in mind that, because of the redundancy and compensation of 
the regulatory machinery, the interpretation of targeted gene mutation is 
sometimes not straightforward in unravelling the physiology. Modifying the 
synthesis of a particular gene at all sites and developmental stages may 
be a relatively crude way of investigating its functions. Inducible and 
tissue specific knockout animals aimed at depleting a specific gene product 
in a certain tissue and age could lead to a better understanding of the 
system. However, despite these limitations, observations of mice with 
global gene knockouts have shed new light on the understanding of energy 
homeostasis equation, two examples being the study of IL-6 and IL-1RI 
knockout mice.  
 
Administration Routes 
The choice of administration routes was dependent on the aim of the 
study. In Paper II permanent guide cannulae connected to osmotic pumps 
(Alzet Mini-Osmotic Pump Model 2002, Durect, Cupertino, CA) were 
implanted into the brain to facilitate continuous intracerebroventricular 
(ICV) administration in rats. Stereotactic coordinates (0.6 mm posterior to 
bregma, 1.4 mm lateral to midline and 4.0 mm below the outer surface of 
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the skull) were chosen so that the administrated recombinant rat IL-6 
would reach the lateral ventricle. Guide cannulae were held in position by 
dental cement attached to three stainless steel screws driven into the 
skull. The ICV route is a very good way of giving bioactive substances 
directly into the CNS and thereby bypassing the blood brain barrier. The 
injected substance diffuses within the ventricles and can easily affect sites 
close to the ventricle, such as the PVN and ARC of the hypothalamus. It 
should be kept in mind that when a substance is injected ICV several brain 
sites will most probably be affected, as the cerebrospinal fluid flows from 
the lateral to the 4th ventricle and then into the brainstem. 
 
In Paper I and III, mice were treated with daily i.p. injections, which is a 
fairly quick way to administrate a relatively large volume. I.p. injections 
are easy to perform but should be placed in the lower part of the 
peritoneum to avoid penetration of the intestines, which might cause an 
infection and certainly will limit the desired biologic effect of the 
administrated drug. In Paper I mice were given i.v. injections of glucose. 
The i.v. injections mostly provide a very fast uptake to most non-SNS 
tissues and thereby rapid biological effects, as the substance is 
administrated directly into the blood stream. A disadvantage might be that 
much smaller volumes can be injected compared to i.p. injections. 
Furthermore, the animal has to be restrained or sedated, and warmed 
before injection into the tail vein. This is more stressful for the animal and 
the anaesthesia will slow down the metabolism. 
 
Indirect Calorimetry in Metabolic Cages 
Direct calorimetry is based on the assumption that all cellular metabolic 
events ultimately result in heat. Accurate measurement of heat production 
would then give information about the metabolic rate (i.e. direct 
calorimetry). However, in reality heat production is difficult to measure 
precisely and therefore indirect calorimetry has become the most 
commonly used method to measure metabolic rate. This method is based 
on measurements of oxygen consumption, assumed to originate from 
oxidation of nutrients and has proven to be a highly accurate estimate of 
energy expenditure. An animal inhales ambient air that has a constant 
composition and the changes in oxygen and carbon dioxide percentage in 
expired compared with inspired air reflect the ongoing metabolic 
processes.  
 
We have the opportunity to measure oxygen consumption (VO2), carbon 
dioxide production (VCO2) and locomotor activity by two different indirect 
open-circuit calorimetry systems. One Oxymax® system from Columbus 
instruments (Columbus, OH,USA) and one INCA® metabolic system from 
SOMEDIC (Somedic sales, Hörby, Sweden) with an integrated telemetry 
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receiver system from Minimitter. The Oxymax® system was used in Paper 
I, while the INCA® system has been used in Figure 7 in the Summary and 
in a paper not included in this thesis [93]. The mice were conscious and 
unrestrained during the measuring periods in the chambers and had free 
access to food and water. Measurements in the Oxymax® system can be 
performed at room temperature and at thermoneutrality (~30ºC) while 
the ambient temperature can be set anywhere between 4-30ºC in the 
INCA® system. Basal metabolism was assessed in the thermoneutral zone, 
which is the temperature (~30°C) at which the mice do not need to use 
energy to actively maintain its body temperature.  
 
An air sample was withdrawn from each cage every 2nd minutes, and O2 
and CO2 content were measured. These values were used to calculate VO2 
and VCO2. The respiratory exchange ratio (RER) is the ratio of carbon 
dioxide output (VCO2) to oxygen uptake (VO2), that is: RER= VCO2/VO2. 
The RER value will differ depending on the metabolic state. Since 6 units of 
CO2 are produced and 6 units of O2 are consumed when carbohydrates are 
oxidized, RER is equal to 1, whereas RER will fall to around 0.7 when fat 
are being used exclusively for metabolism, as about 16 units of CO2 are 
produced and 23 units of O2 are consumed.  
 
The Oxymax® system is equipped with infrared sensors to detect the 
activity of the animals, and therefore the cages contained no bedding or 
nesting material. The cages were considerably smaller compared to the 
home cages that the mice were used to, which makes locomotor activity 
data difficult to interpret. The small cages may also affect the behaviour of 
the mice. The INCA® system can measure body core temperature, activity 
and heart rate by telemetry (E-Mitters, Mini-Mitter, Oregon, US). An 
advantage of biotelemetry is the possibility to obtain physiological 
measurements with high resolution from freely moving animals, without 
introducing stress by handling. A potential disadvantage is that it is an 
invasive technique that requires surgery, but the risk of adverse effects on 
behaviour and physiological functions can be decreased by increasing 
body-to-transmitter size ratio. INCA® cages are relatively large and 
contain bedding and nesting material, which improve locomotor data.  
 
Correcting oxygen consumption for the metabolically active mass of the 
animal is important when comparing data from animals of different body 
weight and surface/volume ratio. There are several ways of scaling the 
oxygen consumption but none of them are perfect. A widely used formula 
is based on the finding that metabolic rate correlates to the body weight 
raised to the power of 0.75 [94]. Indirect calorimetry measurements 
carried out in animals that are not eating or moving, and are kept in the 
thermoneutral zone show the basal metabolic rate of the mouse. This is a 
measure of all body processes that require energy and are needed for the 
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survival of the animal. Moreover, at thermoneutrality the metabolism will 
correlate directly with the metabolically active body mass (see below). If 
measurements of the metabolic rate are carried out at temperatures below 
the thermoneutral zone, a mouse with higher body weight and increased 
fat mass has, because of better insulation and lower body surface/volume 
ratio, a decreased need of energy expenditure to defend body temperature 
than has a smaller mouse.  
 
Moreover, the proportion of metabolically active tissue varies between 
individuals. Thus, oxygen consumption per gram body weight may falsely 
give too low a value in an obese mouse compared with a lean mouse. One 
way of correcting for differences in body composition is to relate the 
metabolic rate to lean body mass instead of total body mass. However, 
this method assumes that the energy expenditure of the adipose tissue 
can be ignored. Although the metabolic rate of adipose tissue is low, it is 
definitively not zero. Therefore, the metabolic rate expressed per lean 
body mass of a very obese animal might falsely be too high. One way to 
avoid scaling problems is to try to investigate the metabolic rate in mice of 
equal body weight and body composition, i.e. before the onset of obesity if 
studying obese phenotypes. 
 
Glucose and Insulin Tolerance Test 
The glucose reducing effect of insulin treatment was assessed in awake 
animals. Blood was withdrawn from the tail to determine fasting blood 
glucose before a load of human insulin was administered i.p. (1U/kg body 
weight). Further samples were collected 15, 30, and 60 minutes after the 
insulin challenge. Blood glucose levels were determined by an ABL 700 
series analyzer (Radiometer, Denmark) or a blood glucose meter (Accu-
Chek, Roche, Germany). The insulin injection can sometimes cause the 
blood glucose to drop so low that the mice show signs of hypoglycaemic 
shock such as convulsions or coma. This may occur if blood glucose goes 
below 2mmol/L. Animals were observed throughout the test and 
hypoglycaemic individuals were rescued with oral administration or 
subcutaneous injections of glucose solution. To lower the risk of 
hypoglycaemia, the insulin dose was later decreased to 0.5U/kg body 
weight in other experiment. This regimen still caused a robust decrease in 
blood glucose. 
 
Glucose clearance after a bolus dose of D-glucose was measured in fasted 
anesthetized mice. Blood samples were taken from the retrobulbar 
capillary plexus 1, 5, 10, 20, 30, and 50 minutes after an i.v injection of D-
glucose (1g/kg; 10µl/g body weight) into the tail vein. Glucose levels were 
analyzed immediately in blood samples, while plasma samples were 
collected for insulin measurements by ELISA. The injected glucose 
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concentration must be high to keep the injection volume down in obese 
animals; otherwise the large volume may cause heart failure and death. 
Another possible protocol includes i.p. administration of glucose (1g/kg) 
and collection of blood samples from the tail after 30, 60, 90 and 120 
minutes. This setup worked well in our hands for both normal and over 
weight mice, with only small deviations within groups.  
 
DEXA 
Dual energy X-ray absorptiometry (DEXA) is a non-invasive method that 
can be used for determining body fat mass. This technique enabled us to 
measure body composition in sedated animals. During measurement, the 
whole animal was exposed to a small beam of both high and low-energy X-
rays. The absorbance of X-ray energy is different in tissues with different 
densities, and the amount of radiation absorbed when each X-ray is 
passed through the body was measured. The ratio of energy attenuation in 
the luminescent panel separated bone, lean mass and fat tissue. A quality 
control phantom mouse was used for the calibration carried out before 
imaging. Body fat (g) and (%), lean body mass (g) and total bone mineral 
density (g/cm2) and bone mineral content (g) were determined by 
densiometry using a PIXImus imager (GE Lunar, Madison, WI, USA) or a 
Norland pDEXA Sabre (Fort Atkinsson, WI, USA). Fat mass and lean body 
mass were calculated using the PIXImus software (version 2.00) or the 
Sabre Research software (version 3.9.2) together with image analysis 
using the Scion Image software (Scion Corp., MD, USA).  
 
The inter-assay coefficient of variation for the Norland pDEXA 
measurements of percent fat area was increased with decreasing fat mass 
from 1.0% for mice with 30% fat area to 17.6% for mice with 1.4% fat 
area [95]. The large variation for mice with a small fat area indicates that 
the sensitivity of the assay is decreased in very lean mice and that the 
lower sensitivity limit for the Norland pDEXA image procedure is around 
3% fat area. To my notion, available literature does not contain any higher 
sensitivity limit for very obese animals but one may speculate that the 
variation also increase with an increasing fat mass reaching 45-55%. This 
should be kept in mind when investigating very obese animal models.  
 
The values of fat mass obtained by PIXImus showed a low coefficient of 
variation (~2%) and close correlation with chemically extracted fat mass 
[96]. Although, the fat mass weight tended to be overestimated [96], but 
if interested in comparing differences in fat mass between groups and not 
absolute values, this is acceptable as long as the coefficient of variation is 
kept low. And, because of the close relationship for fat and lean mass 
obtained by the two methods, prediction equations can be used to more 
accurately predict body composition.  
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One advantage with the PIXImus is that it is relatively fast. Therefore, 
before and after treatment scans for several animals could be collected 
and average values calculated for different groups.  
 
Magnetic resonance imaging is another imaging technique and is based on 
signals from hydrogen nuclei in fat and water in strong uniform magnetic 
field. This technique was used to quantify fat mass in Paper I. The 
computer software produces illustrative 3-dimensional pictures that show 
certain body fat depots e.g. visceral and subcutaneous fat but the 
technique is time consuming and laborious.  
 
Analysis of mRNA 
Real Time Quantitative PCR Analysis 
PCR is a very sensitive method to detect specifically amplified gene 
products. The advantages of using quantitative real time-PCR for 
measuring mRNA are that a very small amount of RNA is needed for each 
analysis and that the method has a high throughput. Real time-PCR 
analysis makes it possible to quantify specific mRNAs over time by 
combining the 5´nuclease activity of a DNA polymerase and a fluorescent 
probe that span an exon-exon boundary for a specific gene, or a 
fluorescent dye binding to double stranded DNA. The increase in 
fluorescence intensity is proportional to the amount of amplicon produced.  
 
Real time-PCR analysis was used to explore the expression of 
hypothalamic genes of interest. Total RNA was isolated from hypothalamus 
as described in Paper II. In brief: the tissues were homogenized in QIAzol 
Lysis Reagent using a TissueLyser (Qiagen, Sweden) and RNA was isolated 
by a colon kit. cDNA synthesis was performed by iScript™ cDNA synthesis 
kit (BioRad, USA). The RT-PCR was performed on an Mx3005PTM Real-Time 
PCR System (Stratagene, USA). Transcripts were detected using probes 
labelled with FAM in the 5’ end or alternatively, the transcripts were 
detected using the SYBR® Green detection system. Melting curves were 
performed to verify the PCR products.  
 
Using fluorescent reporter probes is the most accurate and most reliable of 
the methods, but also the most expensive. Therefore, SYBR® Green was 
mainly used for detection. One has to keep in mind that double stranded 
DNA dyes such as SYBR® Green will bind to all double stranded DNA PCR 
products, including non-specific PCR products like primer dimers. This can 
potentially interfere with or completely prevent accurate quantification of 
the intended target sequence. However, the problem can be reduced by 
evaluation of primers by amplicon size and PCR efficiencies. All samples 
were run in duplicates and normalized by using mouse acidic ribosomal 
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phosphoprotein PO (m36B4) as an endogenous control. The relative 
expression levels were estimated using the comparative threshold cycle 
method.  
 
In situ Hybridization 
In situ hybridization is a technique that uses a labelled complementary 
RNA strand (i.e. probe) to localize a specific mRNA sequence in a section 
of tissue. mRNA levels were measured with in situ hybridization as 
described in Paper II. In brief, brains were sectioned, transferred to poly-
lysine coated slides and fixed with 4% paraformaldehyde (Sigma, Dorset, 
UK). Oligonucleotide probes complementary to the mRNA of the peptide 
under study were labelled with 35S, slides were incubated with the labelled 
probe overnight and then thoroughly washed and air-dried before 
exposure to X-ray film (Amersham, Buckinghamshire UK). The films were 
developed after 3-5 days, depending on the peptide, and the optical 
densities were measured and compared against a C14-labelled standard of 
known radioactivity (Amersham, Buckinghamshire, UK).  
 
The two different ways of measuring mRNA used in this thesis work are 
both common techniques that have slightly different advantages. The real 
time-PCR technique is very sensitive and can detect very small differences 
in expression levels. Furthermore, several genes can be analyzed rather 
quickly, and from a small tissue sample. However, the in situ hybridization 
technique has one big advantage compared to the real time-PCR in that 
one can determine the exact location and at the same time get a relatively 
good quantification of the mRNA expression of discrete cell groups. 
Nevertheless, this method is time consuming and only a handful of genes 
can be analyzed du to limited numbers of brain sections.  
 
Statistical Analysis 
All analysis were performed using the SPSS statistical software (SPSS, 
Chicago, IL, USA). All values were calculated and presented as average ± 
standard error of the mean (sem), except from when standard deviation 
values were more informative. Comparisons were performed with 
Student’s t-test followed by Bonferroni’s correction when differences 
between more than two experimental groups were analyzed. In some 
experiments one-way ANOVA for repeated measurements was used. Data 
derived from the same animal at several times was analyzed with ANOVA 
for repeated measurements to evaluate differences between experimental 
groups. P values < 0.05 were considered significant. When appropriate, 
values were normalized with logarithmic transformation, using log2 values. 
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SUMMARY OF RESULTS AND DISCUSSION 
Paper I-III: Cytokines Affecting Body Fat Mass 
IL-1RI -/- Mice Develop Mature-Onset Obesity, Paper I 
Wild-type and IL-1RI -/- mice were not different in body weight until five 
months of age, when IL-1RI -/- male and female animals started to 
deviate from wild-type mice. At nine months of age IL-1RI -/- mice were 
20% heavier than wild-type controls. The increased body weight was 
associated with increased body fat mass and increased crown-rump 
length. Even though the IL-1RI animals were longer, they still had an 
increased body mass index (BMI), calculated as the square of body weight 
divided with the square of crown-rump length, indicating that the 
increased body weight was associated with obesity and not only growth. 
The lean body mass in relation to body weight was lower in IL-1RI -/- mice 
compared to wild-type controls but the lean body mass in grams was 
instead increased in IL-1RI -/-. Serum analyses of leptin and insulin-like 
growth factor-1 (IGF-1) confirmed these finding as increased serum levels 
of leptin have been shown to correlate with fat mass and IGF-1 is an 
important growth factor. It seems likely that the increased IGF-1 levels 
play a role in the increased absolute lean body mass and longitudinal 
growth observed in IL-1RI -/- mice. Moreover, it can not be ruled out that 
the increase in IGF-1 also contributes to the development of obesity [97]. 
 
IL-1 seems to possess a tonic fat-suppressing effect in healthy animals, as 
lack of IL-1 activity due to depletion of the IL-1RI, caused an increase in 
fat mass in mice. Additionally, excess IL-1 activity due to IL-1Ra -/- in 
mice caused leanness and resistance to diet induced obesity [69, 70]. 
These studies demonstrate a clear role for IL-1 in body fat regulation. 
Furthermore, the result from this and other studies indicate that four 
different cytokines; IL-1, IL-6, IL-18 and GM-CSF all suppress fat mass, 
probably via CNS effects [35, 57, 70, 98, 99]. Moreover, knockout of IL-
1RI, IL-6, IL-18 and GM-CSF all result in mature-onset obesity, between 
five and six months of age, indicating that the loss of one of these genes is 
not severe enough to alter fat mass in young mice [34, 35, 98, 99]. 
However, IL-6 -/- IL-1 -/- double knockout mice become obese as early as 
13 weeks of age [32]. One may speculate that there is a redundancy 
between cytokines, so that loss of one of them is compensated by others 
in young animals. However, at older age the loss of one cytokine may 
results in obesity only together with an age-related factor. 
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IL-1RI -/- Mice had Decreased Insulin and Leptin Sensitivity, Paper I 
The obesity in older IL-1RI -/- mice was accompanied by a disturbed 
glucose metabolism. Basal serum insulin levels were elevated in IL-1RI -/- 
animals and an insulin tolerance test showed that these animals, after an 
acute injection of insulin, had a reduced stimulation of glucose disposal, an 
indication of decreased insulin sensitivity. However, normal basal glucose 
levels were still seen in these mice compared with wild-type mice. Glucose 
uptake was studied after a bolus dose of glucose i.v.. Plasma glucose 
concentrations were then higher in IL-1RI -/- 50-70 minutes after 
injection, demonstrating a mild impairment of plasma glucose elimination. 
Given that obesity can cause insulin resistance, it is not surprising that the 
obesity in IL-1RI -/- mice is accompanied by decreased insulin sensitivity 
and glucose uptake. In line with this, lean IL-1Ra -/- mice had increased 
insulin sensitivity [69, 70]. 
 
In contrast to the arguments brought forward above, there are also 
reasons to believe that lack of IL-1 activity in IL-1RI -/- mice would 
increase insulin sensitivity. Inflammation in general is associated with 
decreased insulin sensitivity [100], suggesting that these animals lacking 
an important proinflammatory cytokine may have increased insulin 
sensitivity. Furthermore, depletion of IL-6 is associated with increased 
insulin sensitivity in young mice, but this is then converted into insulin 
resistance in older animals (unpublished results). Figure 4B in Paper I, 
indicates that this may also be true for IL-1RI -/- animals, as there was a 
tendency for decreased basal serum insulin levels in four-month-old mice. 
A putative positive effect caused by of lack of IL-1 and IL-6 on insulin 
sensitivity might be masked by the influence of obesity in older animals. 
Although it can not be excluded that IL-1 can induce decreased insulin 
sensitivity at high pathological levels in conjunction with other cytokines, 
available data indicate that lower doses of IL-1 can increase insulin 
sensitivity in vivo [101]. Therefore, IL-1 effects on insulin actions may be 
dose-dependent as well as age-dependent. 
 
It has been suggested that leptin resistance is a contributing factor to the 
development of obesity [102], and IL-1 has been suggested to mediate 
leptin effects in the CNS [103-105]. Therefore, we studied the effect of 
leptin treatment on body weight and food intake in wild-type and           
IL-1RI -/- mice. When given to younger animals, only wild-type mice 
responded to the intermediate dose (25µg/mouse) of leptin, by decreased 
food intake and body weight. Both IL-1RI -/- and wild-type mice 
responded to the higher dose of leptin (120µg/mouse). However, there 
were no effects of the higher dose of leptin when given to older obese    
IL-1RI -/- mice while this dose had effects on body weight and food intake 
in age-matched wild-type animals. Lack of IL-1RI activity in young         
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IL-1RI -/- mice may cause leptin resistance that precedes the development 
of obesity in older animals. This is in line with previous results 
demonstrating that IL-1 activity is important in mediating leptin effects 
[103] and that leptin treatment increases hypothalamic levels of IL-1 
[103, 105]. Taken together, these results suggest that the decreased 
leptin sensitivity seen in young mice with defective IL-1 signalling may 
contribute to the development of mature-onset obesity.  
 
IL-1RI -/- Mice had Higher RER and Lower Locomotor Activity, Paper I 
When total energy expenditure (O2 consumption, ml/min) was measured 
by indirect calorimetry in young IL-1RI -/- and wild-type mice, no 
significant difference was discovered. However, the RER was higher in IL-
1RI -/- during the first six hours during the dark phase. This finding 
indicates that the IL-1RI -/- mice had increased carbohydrate utilization 
rate rather than oxidation of fat as an energy source during this period. 
Similar observations have been made in IL-6 -/- mice [93, 106]. Acute 
central injections of IL-1 or IL-6 increase energy expenditure without any 
effect on RER [34, 107], while continuously ICV administration of IL-6 
during one week seems to decrease RER in rats (Figure 7, unpublished 
results). Suggesting that chronic IL-6 treatment can increase lipid 
utilization, this is in line with several studies that show an increased fatty 
acid oxidation in vivo after infusion of IL-6 in humans [108-110]. One may 
speculate that this decrease in RER would also be seen after central 
chronic IL-1 treatment. However, to my notion, this hypothesis has neither 
been confirmed nor rejected in the literature, and data from IL-1Ra -/- 
mice show a circadian pattern with increased RER during night time and 
decreased RER during day time [69].  
 
Younger IL-1RI -/- mice showed a decreased locomotor activity during the 
first six hours of the night, i.e. at the time when they also had higher RER 
and lower fat burning. On the other hand there was no difference in 
locomotor activity in comparison with wild-type mice, during other parts of 
the 23-hour period measured. This is in line with the decreased locomotor 
activity reported during early night in IL-1β -/- mice [111]. Differences in 
spontaneous locomotor activity or non-exercise activity thermogenesis, 
such as fidgeting, have been discussed in relation to human and rodent 
obesity [7, 112, 113] and both high RER, and low spontaneous activity are 
predictors of obesity in Pima Indians [114, 115]. 
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Figure 7. IL-6 treatment ICV decrease RER 
Decreased RER (VO2/VCO2) in rats continuously treated with IL-6 ICV for one week, 
via osmotic pumps. Vehicle (♦) and rat recombinant IL-6, 250ng/day (○). * p< 0.05, 
calculated with one-way ANOVA for repeated measurements. 
 
IL-1RI -/- Mice had Increased NPY and Decreased Orexin Levels, 
Paper II 
 
The expression of the orexigenic peptides NPY and MCH were increased in 
older IL-1RI -/- animals. In theory, this increase in orexigenic peptides 
could increase the food intake in these animals. However, the food intake 
data are difficult to interpret, as older IL-1RI -/- mice ingested more food 
per day than wild-type animals in absolute amounts, while the food intake 
in relation to body weight was not altered (Paper I). IL-1 may be 
important for the anti-obesity effect of leptin, as IL-1RI -/- mice are partly 
leptin resistant (Paper I) [103], and leptin treatment induces IL-1ß release 
from microglia cells in vitro [116]. However, it remains to be investigated 
whether the enhanced levels of NPY and MCH expression in the present 
study are due to deceased capacity of leptin to suppress the production of 
these peptides in IL-1RI -/- mice.  
 
Obesity prone young IL-1RI -/- mice showed a marked decrease in orexin, 
while there was no difference between older animals. It is unclear whether 
this decrease in orexin expression is of importance for the obesity 
observed in older in IL-1RI -/- animals. Orexin was named due to its 
stimulation of food intake, and orexin neurons are found in the lateral 
hypothalamus, the classic “feeding” centre of the brain [117]. Apart from 
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stimulating appetite, orexin causes arousal instead of sleep, and enhances 
the activity of the SNS, body temperature, locomotor activity and 
metabolic rate [117, 118].  
 
The promotion of energy expenditure by endogenous orexin seems to be 
more pronounced than the effect on food intake. Also the overall effect of 
endogenous orexin seems to be to decrease obesity, as genetic depletion 
of the orexin gene or of orexin producing neurons, results in an obese 
phenotype [119, 120]. Therefore, endogenous orexin may suppress 
obesity by stimulating energy expenditure more than energy intake. As 
mentioned above, young IL-1RI -/- mice have decreased locomotor 
activity (Paper I), but it remains to be investigated whether decreased 
orexin expression could mediate these effects. Orexin axons show a 
widespread projection to many different brain areas, and one of the 
densest projections of orexin neurons are found in the PVN [117]. 
Moreover, direct injections of orexin into the PVN have been shown to 
increase spontaneous physical activity (SPA), independently of feeding 
behaviour [121], while loss of orexin activity results in hypophagic animals 
that are much less active [120]. However, feeding with high fat diet has 
been reported to stimulate orexin expression in the perifornical lateral 
hypothalamus [122, 123] and to decrease SPA [122]. It has been 
suggested both that fat-induced increase in orexin expression could cause 
more craving for high fat diet via effect on the reward systems, and that it 
could thereby increase the risk of obesity [122, 124]. To sum up, the role 
of orexin in body fat regulation seems to be complex and not thoroughly 
understood. 
 
We found no change in hypothalamic POMC expression in IL-1RI -/- mice, 
although IL-1 may stimulate POMC expression [125]. The reason for this 
discrepancy is unknown but could be due to the fact that only a subset of 
ARC POMC neurons are regulated by IL-1β [125], and that measurement 
of POMC expression in the whole hypothalamus may not detect alterations 
in subgroups of POMC neurons. In addition, CRH expression levels were 
not altered in IL-1RI -/- mice even though IL-1 has been shown to 
stimulate the HPA axis and activate parvocellular neurons in the PVN [126-
128]. However, the redundancy between different cytokine actions might 
cover for the loss of IL-1 signalling, i.e. IL-6 may induce sufficient CRH 
expression in IL-1RI -/- mice. 
 
IL-6 -/- Mice had Decreased CRH Levels, Paper II 
The levels of CRH mRNA in the hypothalamus were decreased by 40% in 
older IL-6 -/- mice, suggesting that endogenous IL-6 is a physiologic 
regulator of hypothalamic CRH expression. These results were supported 
by the finding that CRH mRNA levels in the hypothalamus were enhanced 
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by 50% after chronic ICV treatment with IL-6 to rats, indicating that IL-6 
stimulates CRH expression via an effect at the CNS level. This is in line 
with the solid association between IL-6 and CRH expression after induction 
of inflammation [129-131], which has now been extended to healthy 
animals. The decreased CRH expression could partly explain the decreased 
activity of the SNS and subsequent obesity in healthy IL-6 -/- mice [34, 
93, 106], as low CRH levels have been associated with decreased 
activation of SNS and decreased energy expenditure. This, in turn, could 
lead to obesity over time [132]. It has been reported that chronic central 
IL-6 exposure is associated with increased uncoupling protein (UCP)-1 
expression in brown adipose tissue (BAT) and that this effect is dependent 
on the SNS [133]. Based on these findings, we hypothesize that 
endogenous IL-6 stimulates energy expenditure and thermogenesis, and 
decreases obesity via enhanced expression of CRH in the PVN and 
subsequent activation of the SNS. 
 
Leptin plays an important role in the regulation of energy balance- 
stimulated thermogenesis [14, 18]. Leptin induces expression of CRH 
mRNA in the PVN [134] and activates sympathetic nerves to increase  
UCP-1 activation in BAT. Moreover, it has been shown that co-infusion of a 
CRH antagonist can block the effects of leptin on feeding, adiposity and 
UCP-1 expression [135, 136], indicating that CRH neurons may be an 
important mediator of these effects of leptin. In this study, despite the fact 
that they have been shown to have high leptin levels at this age [34], 
older IL-6 -/- mice had decreased CRH expression, suggesting that central 
IL-6 is at least as important as leptin in stimulating CRH expression. 
 
Altered Cytokine Expression in IL-6 -/- and IL-1RI -/- Mice, Paper II 
The hypothalamic expression of IL-1ß was increased in IL-6 -/- and in 
IL1RI -/- mice. In contrast, the hypothalamic expression of IL-6 was 
decreased in IL-1R1 -/- animals. These results are in line with the 
indications that IL-1 and IL-6 interact to suppress fat [32-34] and that this 
effect is exerted at the hypothalamic level [34, 57, 58, 103]. The 
decreased IL-6 expression in IL-1RI -/- mice indicates that endogenous IL-
1 can stimulate hypothalamic IL-6 production in healthy mice. In sick 
mice, IL-6 has been shown to be necessary for fever response induced by 
IL-1ß [137]. The up-regulated IL-1ß expression in IL-6 -/- mice could 
possibly reflect a negative feedback inhibition of hypothalamic IL-1 
production by IL-6 under baseline conditions, as suggested previously to 
be the case during pathologic conditions [138].  
 
Our results also indicated that IL-6 and IL-1 could inhibit their own 
expression at the hypothalamic level, as lack of biological activity exerted 
by either of these genes increased the mRNA expression of the same 
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gene. This is in contrast to previous results that indicate that IL-6 and IL-1 
stimulate their own production [138]. One reason could be that we study 
basal homeostatic conditions, which may differ from feed forward 
regulation during pathologic conditions, such as inflammation. 
Alternatively, the hypothalamus may differ from other parts of the body.  
 
Taken together these results strengthen our view regarding an interaction 
between IL-6 and IL-1 at the hypothalamic level during baseline 
conditions, e.g. in suppression of body fat (Figure 8).  
 
Altered Cytokine Expression during Fast, Paper II 
Hypothalamic IL-1β was decreased in wild-type mice after fast, while CRH 
and TNF-α levels were increased after fast. The decreased hypothalamic 
IL-1ß expression is likely, at least partly, to be explained by decreased 
serum leptin levels in conjunction to fast, as leptin has been reported to 
stimulate hypothalamic IL-1ß production [103, 116, 139, 140]. The 
decreases in IL-1ß could be of importance for the decreased immune 
response and/or energy expenditure that is seen in response to fasting 
[103]. However, contradictory results have been reported in fasted rats, 
where one study shows elevated [86] and another decreased [105] 
hypothalamic IL-1ß levels. It remains to be further evaluated whether IL-1 
is consistently decreased after long term fast in these different species.  
 
     
IL-1ß IL-1RI IL-6 IL-6Rαgp130
Anti-obesity
effect
IL-1Ra sgp130
 
Figure 8. Anti-obesity effect mediated by IL-1 and IL-6 
IL-6 expression and secretion is induced by IL-1β. There is also evidence that IL-6 
in turn regulates the release of IL-1. The effect of IL-1β and IL-6 can be inhibited by 
the endogenous antagonist IL-1Ra and soluble gp130, respectively. 
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CRH is assumed to stimulate SNS and energy expenditure [141, 142], and 
so the increased CRH levels could not easily explain the suppression of 
energy expenditure that are seen during fast. Regarding SNS activity after 
fasting, there is a discrepancy in the literature [143, 144]. The finding that 
CRH is elevated in wild-type animals after 18 hours fast could be of 
importance for the increase in ACTH and corticosterone levels observed 
during this state [143, 145]. In line with this assumption, a diminished 
HPA axis response is observed in CRH -/- animals after fast [145]. Still, it 
is well known that the HPA axis and the SNS are regulated by different 
groups of CRH containing neurons in the PVN [138] and we have not yet 
been able to determine which of the parvocellular neurons that express the 
elevated CRH levels. 
 
LIF Treatment Reduced Body Fat Mass, Paper III 
There is an increasing body of data indicating that cytokines play a role in 
body fat regulation. Therefore, we investigated whether an additional 
cytokine of the IL-6-receptor family, LIF, possessed anti-obesity effects in 
an obese ovariectomized (OVX) mouse model. OVX mice are known to 
gain body fat and we observed a significant increase in body weight and 
fat mass (~30%) as well as a three-fold increase in leptin levels after OVX.  
 
It is well recognised that the exposure to estrogens decreases fat mass, 
especially visceral fat [146-149]. Estrogen replacement therapy has been 
shown to enhance the expression of LIFR [150]. Therefore, we 
hypothesised that LIF and estradiol may interact in a way where estradiol 
is necessary for the effects of LIF. However, we found that LIF treatment 
to OVX mice caused a significant reduction in the weight of white fat 
depots and serum leptin levels, suggesting that estrogen signalling is not 
required for this effect.  
 
LIF is thought to play a role in the cachexia syndrome by the inhibition of 
adipocyte lipoprotein lipase activity. [83, 151]. In contrast, LIF does not 
decrease lipoprotein lipase activity in skeletal or cardiac muscle [151]. In 
rats, systemic LIF administration increases hepatic triglyceride secretion 
by stimulating both lipolysis and de novo synthesis of fatty acids [152] 
(Figure 9). Taken together, these data indicate that LIF-induced effects on 
suppression of body fat include actions on fat metabolism and that these 
actions in mice are not dependent on endogenous ovary-derived 
estrogens.  
 
The dose of LIF used in our experiment also caused a significant decrease 
in BAT. However, the reduction in brown fat mass was not accompanied by 
altered UCP-1 or -3 protein expression. UCP-1 is used to generate heat by 
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non-shivering thermogenesis and is restricted to brown fat while UCP-3 is 
mainly expressed in skeletal muscle. The primary function of UCP-3 is not 
the regulation of energy metabolism but nevertheless includes 
involvement in the regulation of mitochondrial fatty acid transport and 
regulation of glucose metabolism [153]. UCP-1 protein expression is an 
index of thermogenesis in BAT [154], and hence the unchanged UCP-1 
protein levels suggest that the weight reducing effects of LIF did not 
involve increased energy expenditure through non-shivering 
thermogenesis.  
 
The finding that UCP-3 levels were unchanged supports the assumption 
that LIF does not influence energy metabolism in BAT. These data are 
supported by the finding that central administration of an adeno-
associated viral vector encoding LIF did not affect UCP-1 protein 
expression [56]. However, LIF has been reported to decrease food intake 
when given ICV [56, 155], suggesting that LIF induces its weight reducing 
effect mainly through reduced appetite, possibly via a central effects. Yet, 
the literature studied does not hold any information about food intake after 
subcutaneous or i.p. injections of LIF [156, 157], leaving the question 
open whether peripheral LIF treatment can induce anorexia in a similar 
way as peripheral IL-1β injection [158]. It is a weakness that we did not 
measure food intake throughout the study. It would have been interesting 
to see whether LIF treatment could reverse the increase in food intake that 
has been reported after OVX in mice [159], and whether or not peripheral 
LIF treatment has the potential to induce anorexia.  
 
OVX mice had decreased uterus weight and trabecular bone mineral 
density, and increased thymus weight. LIF treatment reversed the 
decrease in thymus weight but had no effect on uterus weight or bone 
mineral density. It is well known that OVX increases thymus weigh and 
that estrogen replacement therapy can reverse this effect [160-162].  
 
Since estradiol enhances LIFR expression [150] it is possible that 
estrogen-mediated stimulation of LIF responsiveness also mediates this 
effect of endogenous estrogens. However, this well established thymus 
reducing effect of LIF is not dependent on endogenous estrogens [156, 
157, 163]. Another possibility is that LIF indirectly suppresses thymus 
weight by decreasing body fat and leptin secretion. Thymus atrophy is a 
prominent feature of malnutrition, and starvation of mice significantly 
reduced thymocyte number [164]. These starvation-induced thymus 
changes were prevented by administration of exogenous leptin [164], 
indicating that circulating leptin levels have direct effect on thymus weight.  
 
LIF treatment did not reverse the drastic decrease in uterine weight or 
bone mineral density after OVX. Therefore, these effects by endogenous 
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estrogens are likely to be independent of LIF. Another possibility, however, 
could be a tissue specific lack of LIFR in bone and uteri after OVX, due to a 
pronounced dependence of endogenous estrogens for LIFR expression in 
these organs [150]. 
 
The finding that LIF suppresses fat mass in OVX mice is in line with 
previous results that show that systemic LIF treatment to monkeys [156, 
165] and mice [157] and central LIF gene therapy in rats [56] all decrease 
body weight. This may be a part of a generalized effect of cytokines acting 
through the IL6ST/gp130.  
 
Recent research has focused on the role that gp130 receptor ligands may 
play as potential targets of obesity. We have shown that IL-6 itself 
selectively decreases fat mass, possibly via a central effect that increases 
energy expenditure [34, 57]. Another IL-6 family member, CNTF, mimics 
the biological actions of leptin by acting on the same genes in the ARC, 
resulting in decreased food intake and weight loss [166]. The anorexigenic 
and anti-obesity effects of this factor in the CNS seem to be independent 
of the leptin system and appear to be effective in obesity [166, 167], 
although this condition is often accompanied by leptin resistance          
(see Introduction, leptin section). CNTF and IL-6 also act on metabolic 
signalling pathways in peripheral tissue by the activation of AMPK [168-
170] and increased fat oxidation [109, 110, 170], which is of primary 
importance to the regulation of body weight and insulin resistance. 
However, the major anti-obesity effect of these gp130 ligands may be 
exerted via the brain [56, 57, 167]. 
 
LIF and the LIFR in mice are expressed in the pituitary and in the PVN, 
DMN and ARC [90, 91] the sites of production, release and actions of 
neuropeptides implicated in the hypothalamic control of energy intake and 
expenditure. One may speculate that LIF could act on anorexigenic 
neuropeptides in the PVN and ARC, i.e. POMC and CRH, as ICV injections 
of LIF decreased food intake [56, 157]. During inflammation, cytokines 
that stimulate corticotroph POMC expression and ACTH secretion, e.g. LIF, 
are produced both peripherally and within the hypothalamus and pituitary 
[83, 171]. POMC expression in the pituitary leads to the release of ACTH 
and a stimulated HPA axis [83, 172]. The HPA axis is known to influence 
the energy homeostasis, and may contribute to the fat suppressing actions 
of LIF (Figure 9).  
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Figure 9. Working hypothesis regarding central and peripheral effects 
mediating LIF-induced fat suppressing actions.  
Net effect after peripheral LIF stimulation may lead to increased fat utilization, 
which is in line with other cytokines, e.g. IL-6, that have also been shown to 
stimulate fat oxidation. Central actions of LIF involve HPA axis activation and 
possibly decreased food intake due to POMC expression in the hypothalamus. 
Lipoprotein lipase (LPL), fatty acid (FA) 
 
In conclusion, LIF has been shown to exert anti-obesity effects in various 
animal models [56, 156, 157], and we can add to the body of knowledge 
that such an effect can also be seen in obese mice in the absence of 
ovarian estrogens. 
 
Paper IV: Cytokine Signalling affecting Myocardial 
Infarction 
 
An IL6ST/gp130 SNP was Associated with Myocardial Infarction 
It has become clear that inflammation is a key component in the 
development of atherosclerosis and myocardial infarction, as suggested in 
the so called inflammation hypothesis [173, 174]. Although it is 
established that there is a link between inflammation and cardiovascular 
risk, with the latter largely being genetically determined, there are few 
genetic variants of the immune system that have been linked to 
cardiovascular disease including myocardial infarction [175]. For that 
reason we investigated the association between an IL6ST/gp130 
polymorphism, function and risk of myocardial infarction.  
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In a prospectively followed hypertensive cohort we found that the 
148Arginine (Arg) variant of the gp130 receptor was associated with 
decreased risk of myocardial infarction. Patients and controls were 
matched for sex, age and smoking status and the significantly decreased 
odds ratio for getting a myocardial infarction when carrying the Arg+ allele 
was still valid after adjustment for all significant risk factors for myocardial 
infarction in this study (Figure 10). This was in support of the gp130 
Glycine(Gly)148Arg single nucleotide polymorphism (SNP) as an 
independent risk factor for myocardial infarction, together with leptin and 
high density lipoprotein (HDL), which are both associated with obesity. 
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Figure 10. Increased OR for myocardial infarction in Arg+ individuals 
Odds ratio (OR) and 95% confidence interval (CI) for getting myocardial infarction 
in arginine carrying (Arg+) individuals compared to non-carriers. Both univariate 
analysis (p=0.02) and multivariate analysis (p=0.02), with adjustment for all 
significant risk factors for myocardial infarction in this study, are shown. 
 
An IL6ST/gp130 SNP Showed Lower Proliferation Rate and STAT-3-P 
Cells from a cell line that lacks endogenous gp130 were stably transfected 
with the two gp130 SNP variants. We found no significant difference in cell 
surface expression of gp130 between the two 148Gly and 148Arg variants. 
When the cell lines were stimulated with Hyper-IL-6, a factor consisting of 
coupled IL-6 and soluble IL-6Ralpha [82], the 148Arg variant proliferated 
less in response to gp130 stimulation as compared to cells transfected with 
gp130 148Gly. However, there was no difference in proliferation rate when 
cells were stimulated by IL-3.  
 
The receptors for IL-3 are endogenously present on the used cell line, and 
the signalling pathways for IL-3 are separate from those for Hyper-IL-6. 
The similar effects exerted by IL-3 in the two cell variants therefore 
indicate that the decreased proliferation after Hyper-IL-6 stimulation in the 
148Arg cell line specifically is due to impaired binding to, or signalling via 
the gp130 receptor. Furthermore, the time dependent stimulation of  
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STAT-3 phosphorylation by Hyper-IL-6 was consistently lower in cells 
expressing the 148Arg gp130 variant, while there was no difference in the 
levels of non-phosphorylated STAT-3 between the 148Gly and 148Arg cell 
lines.  
 
These results support that the 148Arg variant is associated with decreased 
biological activity. This assumption is further supported by structural 
modelling, that pointed towards a change in stability and functional 
properties in the gp130/IL-6Rα complex after substitution of a glycine to 
an arginine in position 148. Still, any conclusion about the mechanistic 
effects of the Gly148 to Arg148 substitution requires further experiments, 
for instance to monitor any differences in subunit assembly or gp130 
binding affinity for the different IL-6 family ligands. However, it could be 
postulated that the decreased risk of myocardial infarction in people 
carrying the Arg+ allele is partly due to decreased gp130 activation.  
 
A recent study showed that hepatocyte-specific gp130 -/- mice on an 
atherosclerosis-prone genetic background, apolipoprotein E (apoE) -/- 
mice, had less aortic atherosclerosis with a reduced macrophage-positive 
plaque area, compared to mice with apoE -/- only [63]. Such organ 
specific gp130 -/- models are needed to study gp130 deficiency in relation 
to acute phase response, as complete lack of gp130 results in death in 
utero [176]. These hepatocyte specific gp130 -/- animals have a 
significantly reduced acute phase response after feeding with a high fat 
diet, and isolated macrophages showed reduced migration after 
stimulation [63]. Since macrophage migration is involved in the formation 
of foam cells that are found in atherosclerotic plaques, the decreased 
migration can possibly mediate the decreased plaque area seen in these 
animals.  
 
Collectively, these findings show that the acute phase response plays an 
important role in the formation of atherosclerosis and that the 
development of atherosclerotic lesions can be reduced by an impaired 
gp130 signal transduction.  
 
Although the exact mechanism for the results observed in Paper IV is 
unknown, these data are clearly in line with the inflammation hypothesis 
for CVD. Gp130 is the common signal transducer for the IL-6 cytokine 
family [66] and gp130 activation is regarded as a key event in 
inflammation. It is widely expressed in different cell types, but it may be 
noted that gp130 is expressed in both endothelial cells and smooth muscle 
cells of coronary arteries [177].  
 
The fact that gp130 has a key role in mediating proinflammatory effects 
makes it a logical regulator of inflammation that may be altered by genetic 
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variations. However, it can not be excluded that the degree of gp130 
activation could affect the risk of myocardial infarction via                   
non-inflammatory routes. There are indications that gp130 is essential for 
the hypertrophic response to pressure overload and for the inhibition of 
apoptosis in myocytes [178-180]. Moreover, cardiotrophin-1, a cytokine 
acting via gp130, has been reported to stimulate production in endothelial 
cells of  endothelin-1 [181]. This factor, in turn, can induce 
vasoconstriction and proliferation of smooth muscle cells, which can 
increase the risk of myocardial infarction [182]. Moreover, proliferation of 
smooth muscle cells might also be promoted by the gp130 activation seen 
in these cells [177]. 
 
The risk of atherosclerosis and cardiac disease is partly genetically 
determined, by multiple genomic loci interacting with the environment 
[183]. Some of these genetic variations may modulate the inflammatory 
response and consequently alter susceptibility to CVD. In spite of this, 
there are a limited number of immune related polymorphisms that have 
been reported to affect the risk of myocardial infarction. Two examples are 
the Toll-like receptor 4 Asp199Gly polymorphism [184] and the IL-6 
promoter -174G/C SNP, which have been associated with risk of CVD. 
However, polymorphism studies should always be interpreted with caution, 
as they only show associations, and not proof, of cause-effect relations. 
For instance, the association seen in this paper could be due to linkage 
disequilibrium between the Gly148Arg polymorphism and another 
polymorphism that is affecting the risk of myocardial infarction.  
 
The linkage of a number of polymorphisms in the IL6ST/gp130 gene, 
including the Gly148Arg SNP, were further investigated by Luchtefeld et. 
al., and the haplotype analysis showed that nine of these SNPs, including 
Gly148Arg, fall into one block with strong linkage disequilibrium. One SNP 
was significantly associated with cardiovascular artery disease, while the 
Gly148Arg polymorphism showed a trend for association with 
cardiovascular artery disease [63]. Even though it has not been fully 
evaluated which polymorphisms and which alleles that are associated with 
increased and decreased risk of CVD, these data provides critical evidence 
that gp130 plays an important role in human CVD. 
 
In conclusion, the Gly148Arg polymorphism of the IL6ST/gp130 subunit of 
the IL-6 receptor family was associated with decreased risk of myocardial 
infarction, also when several conventional risk factors were taken into 
account. The relevance of this clinical finding was supported by the results 
from cell studies and by studies on hepatocyte specific gp130 -/- apoE -/- 
double knockout mice. This finding may add to a still limited but growing 
list of immune related polymorphisms that could provide molecular genetic 
explanations for the inter-individual variations in susceptibility to CVD. 
CONCLUDING REMARKS 
 
47 
CONCLUDING REMARKS 
During recent years, it has become clear that obesity is linked to actions of 
the immune system. Leptin is secreted by adipocytes and decreases 
appetite and increases energy expenditure via effects on the 
hypothalamus. However, there is now evidence that leptin plays a role also 
in the regulation of the immune system and the metabolism during 
infection. Conversely, we believe that cytokines, in addition to regulating 
the immune system, can be important for the regulation of metabolism 
during health. This thesis has focused on the metabolic effects of three 
such cytokines, IL-1, IL-6 and LIF. These cytokines are expressed in 
diverse tissues, acting on short distances, i.e. in auto- and paracrine 
signalling, but are also released into the blood stream, which enables 
endocrine effects. 
 
Depletion of IL-6 or IL-1RI in knockout mice results in mature-onset 
obesity, indicating that IL-1 and IL-6 activation possesses a tonic fat-
suppressing effect in healthy animals. IL-6, IL-1 and their receptors and 
the endogenous IL-1Ra are all expressed in the CNS, including the 
hypothalamus, and the metabolic effects of IL-6 are more pronounced 
when it is administrated centrally, as opposed to peripherally, highlighting 
the importance of central actions of IL-6. The central effects of IL-1 and 
IL-6 include responses known to be mediated via the SNS, e.g. increased 
energy expenditure, increased heart rate and increased blood pressure. It 
is not yet known where in the CNS IL-6 and IL-1 exert their effects, but 
there is evidence that IL-6 increases the production of CRH and IL-6 -/- 
mice have decreased levels of CRH in the hypothalamus. CRH is an 
important stimulator of the HPA axis and SNS-outflow during stress. 
Therefore, the results above are in line with the finding that stress-induced 
SNS-outflow seems blunted in IL-6 -/- mice.  
 
IL-1RI -/- mice have decreased expression of the obesity suppressing 
peptide orexin at young age and enhanced expression of the obesity 
promoting peptides NPY and MCH at older age. This can constitute a 
possible mechanism contributing to the mature-onset obesity.  
 
The obesity in IL-1RI -/- mice was accompanied by decreased insulin and 
leptin sensitivity. In humans, circulating IL-6 is increased in obesity and 
suggested to aggravate insulin resistance. Although it can not be excluded 
that IL-1 and IL-6 can decrease insulin sensitivity at high pathological 
levels in conjunction with other cytokines, available data indicate that 
lower doses of IL-1 and IL-6 can increase insulin sensitivity in vivo, 
possibly by decreasing obesity. Therefore, an assumed positive effect of 
lack of IL-1 and IL-6 on insulin sensitivity might be masked by the 
influence by obesity in older animals. 
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Inflammation is a key component in the development of atherosclerosis 
and systemic inflammation is often associated with increased risk of 
cardiovascular events, i.e. myocardial infarction, stroke and peripheral 
artery disease. In addition, obesity is associated with increased risk of CVD 
and is linked to a state of chronic inflammation, as overweight and obese 
subjects have elevated serum levels of inflammation markers. Moreover, it 
has been hypothesized that proinflammatory cytokines from adipose tissue 
contribute to the chronic inflammation and thereby also to CVD.  
 
In a prospectively followed hypertensive cohort we found an association 
between gp130, a key component in the inflammatory signal pathway, and 
myocardial infarction. The less common 148Arg variant of the gp130 
receptor was associated with decreased risk of myocardial infarction. Cell 
signalling studies indicated that the 148Arg variant is a less potent inducer 
of cell signalling in response to IL-6, suggesting that the acute phase 
response plays an important role in the formation of atherosclerosis, and 
that the development of atherosclerotic lesions can be reduced by an 
impaired gp130 signal transduction. We, and others, have provided 
evidence that variations in gp130 activity can influence the risk of 
atherosclerosis, coronary artery disease and myocardial infarction. 
 
An additional cytokine, LIF, also have metabolic effects, seen as decreased 
fat mass. It seems fascinating that several immune factors also seem to 
have body fat regulating properties in healthy individuals, with no evident 
immune activation. Like other biological mediators, the effects of IL-1, IL-6 
and LIF depend probably on the concentration, the site of action and the 
presence of interacting factors. IL-1, IL-6 and LIF have been shown to be 
involved in the regulation of energy intake and expenditure, affecting body 
fat mass, and these effects in the long run may protect against weight 
gain, obesity and metabolic disturbances. In addition, variations in 
cytokine signalling via gp130 can influence the risk of cardiovascular 
disease. Therefore, we hypothesize that cytokines and immune regulating 
factors can provide new drug targets for obesity, and that these new 
targets may act on metabolic disturbances from a different angle. 
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Denna avhandling visar att fetma är kopplat till den del av immunförsvaret 
som kallas det medfödda immunsystemet. Det medfödda immunförsvaret 
är kroppens första försvarslinje som snabbt kan producera 
immunstimulerande ämnen, så kallade cytokiner, som svar på en 
infektion. I denna avhandling har tre av dessa cytokiner studerats mer 
ingående; interleukin-1 (IL-1), interleukin-6 (IL-6) och leukemi-
inhiberande faktor (LIF).  
 
Vi har tidigare funnit att om man slår ut delar av det medfödda 
immunsystemet (den immunstimulerande cytokinen IL-6) hos möss blir 
dessa fetare än vanliga möss. Vi har nu studerat en annan musmodell som 
saknar receptorn för IL-1. Eftersom IL-1 binder till IL1-receptorn för att 
utöva biologiska effekter, är IL-1-aktiviteten utslagen i möss utan IL-1-
receptor. Vi har nu funnit att också dessa möss utvecklar fetma.  
 
Insulin frisätts för att hjälpa kroppen att ta upp sockret i blodet efter 
måltider. De feta mössen som saknar receptorn för IL-1 var mindre 
känsliga för insulin. Minskad insulinkänslighet anses vara ett förstadium till 
sjukdomen diabetes med högt blodsocker, vilken ofta ses i samband med 
fetma. Avsaknad av IL-1-aktivitet ledde även till en minskad 
fettförbränning och en minskad fysisk aktivitet, faktorer som tros spela roll 
för utvecklingen av fetma. När vi undersökte hypotalamus, den del av 
hjärnan som reglerar födointag och ämnesomsättning, visade det sig att 
möss utan IL-1-receptorer hade påverkade nivåer av signalsubstanser som 
tidigare visats reglera födointag och kroppsfett. IL-1 och IL-6 påverkade 
också varandras nivåer i hypotalamus. Därför drar vi slutsatsen att IL-1 
och IL-6 påverkar risken för fetma genom att samverka i det område i 
hjärnan som styr födointag och ämnesomsättning. Det verkar troligt att 
IL-1 och IL-6 minskar fettmassan genom att öka ämnesomsättningen, 
kanske särskilt fettförbränningen. 
 
Behandling med cytokinen LIF visade sig kunna minska fettmassan hos en 
musmodell som efterliknar kvinnor i klimakteriet. Dessa möss har mycket 
låga östrogennivåer och tenderar, på grund av att de fått äggstockarna 
bortopererade, att gå upp i vikt. LIF verkar alltså kunna minska 
fettmassan oberoende av östrogen. Mekanismen bakom den minskade 
fettmassan är okänd men möjligen skulle LIF kunna verka genom att öka 
fettförbränningen och minska födointaget. Detta genom att på samma sätt 
som IL-1 och IL-6 påverka hypotalamus, den del av hjärnan som reglerar 
energiintag och ämnesomsättning. 
 
Länge trodde man att fettvävnaden endast var en lagringsdepå för fett 
(lipider), men modern forskning har visat att fettväven även insöndrar en 
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mängd signalämnen, bland annat cytokiner, till blodet. Av dessa är många 
inblandade i energibalansen, inklusive IL-1, IL-6 och LIF. Via transport 
med blodet kan de nå hjärnan och där utöva effekter på kroppens totala 
fettmassa. 
 
De senaste åren har man funnit att fetma på olika sätt är sammankopplat 
med vårt immunförsvar. Bland annat har man upptäckt att fetma orsakar 
en kronisk, så kallad låggradig inflammation i fettväven, vilket leder till 
insöndring av inflammatoriska komponenter i blodet. Dessa komponenter 
kan i sin tur påverka inflammatoriska sjukdomsförlopp som till exempel 
åderförfettning, som kan ger upphov till hjärtinfarkt och stroke.  
 
Vi har undersökt sambandet mellan en receptor för IL-6 och LIF och 
hjärtinfarkt. I studien ingick nästan 1500 män och kvinnor i övre 
medelåldern. De som hade en medfödd svagare variant av denna receptor 
hade i genomsnitt 50% lägre risk att drabbas av hjärtinfarkt än de med 
den mer vanligt förekommande receptorformen. Den minskade risken för 
hjärtinfarkt skulle kunna bero på att dessa individer inte är lika känsliga 
för cytokiner som IL-6 och LIF då receptorn har nedsatt funktion. För en 
person som är i riskzonen att drabbas av en hjärtinfarkt, och som kanske 
har flera riskfaktorer för hjärt-kärlsjukdom, kan detta vara av betydelse 
för den totala riskbilden. Studier i möss bekräftar att denna receptor kan 
vara inblandat i utvecklingen av hjärt-kärlsjukdom.  
 
Fetma innebär ett akut globalt hälsoproblem, som ökar risken för 
åldersdiabetes, hjärt-kärlsjukdom och tidig död. Den ökade fetman hotar 
därmed det allmänna hälsotillståndet världen över, samtidigt som dagens 
läkemedel mot fetma är bristfälliga. Denna avhandling visar att 
cytokinerna IL-1, IL-6 och LIF är delaktiga i regleringen av 
energiomsättningen och mängden kroppsfett och att IL-1 och IL-6 delvis 
utövar sina effekter via hjärnan. Att immunreglerande faktorer nu visats 
delta i reglering av energiförbrukning och kroppsfett kan leda till nya 
läkemedel som kan angripa fetma på ett helt nytt sätt. 
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